Meta AnalysisID 2514

支气管肺泡灌洗液半乳甘露聚糖检测用于免疫功能低下患者侵袭性曲霉病的诊断 [Cochrane方案]

CRD42017055091

To assess the diagnostic accuracy of galactomannan detection in BAL for the diagnosis of invasive pulmonary aspergillosis in people who are immunocompromised, at different cut-off values for test positivity, in accordanc

Back to Browse

Relationship Network

Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.

Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...

Record Fields

Scalar fields from the final meta_analysis record.

Meta Analysis Id
2514
Evidence Id
11072
Core Evidence Id
11072
Source Meta Analysis Id
2465
Herb2 Meta Analysis Id
HBMA002465
Crd Id
CRD42017055091
Title
Galactomannan detection in broncho-alveolar lavage fluid for invasive aspergillosis in immunocompromised patients [Cochrane Protocol]
Review Question
To assess the diagnostic accuracy of galactomannan detection in BAL for the diagnosis of invasive pulmonary aspergillosis in people who are immunocompromised, at different cut-off values for test positivity, in accordance with the Cochrane Diagnostic Test Accuracy Handbook. Secondary objectives Our secondary objective is to study several possible sources of heterogeneity, see 'Investigations of heterogeneity'.
Study Type Included
Eligible studies will be those that assessed the diagnostic accuracy of galactomannan detection in BAL. The galactomannan ELISA can be assessed alone or in comparison to other tests.
Condition Being Studied
Invasive aspergillosis (IA) is a common and life-threatening opportunistic mycosis. Mortality in people diagnosed with this condition varies depending on the clinical setting, but ranges from 30% to 70% (Aisner 1977; Robenshtok 2007; von Eiff 1995). IA is caused by ubiquitous spores of Aspergillus spp., inhaled by everyone on a daily basis, which can cause invasive disease in the case of a failing immune system (Chotirmall 2013). As invasive aspergillosis only occurs in people with immune deficiency the incidence varies, depending on the degree of immune deficiency. In people who are highly immune deficient, such as people with acute myeloid leukaemia receiving highly intensive chemotherapy, the incidence can exceed 5%. Mainly because of the increasing application of immunosuppressive treatments, especially highly intensive chemotherapy, prolonged corticosteroid therapy and stem cell transplantation (Kaneko 2001; Rubio 2009), the incidence is increasing. Most often the lungs or airways (or both) are the site of infection. But invasive aspergillosis can also occur in the nasal sinus, central nervous system, skin, gastro-intestinal tract, the deep structures of the eye, and prosthetic heart valves; or may give rise to a disseminated infection.
Participant
Participants that have been tested to diagnose or exclude IA using galactomannan detection in BAL.
Animal
Human Disease Modelled
Intervention
The commercially available galactomannan sandwich ELISA (Platelia™) performed on BAL will be the test under evaluation. Studies addressing detection in serum and other body fluids will be excluded.
Comparator Control
The galactomannan ELISA can be assessed alone or in comparison with other tests.
Main Outcome
Diagnostic test accuracy.
Outcome Measure
Additional Outcome
None.
Study Method
Diagnostic, Systematic review
Keyword
MeSH headings have not been applied to this record.
Contact
Koen de Heer [email protected]
Organisational Affiliation
The Cochrane Collaboration http://www.cochrane.org/
Funding Source
None specified
Other Selection Criteria
Final Publication
Same Topic Review
Published Protocol
Review Type
Language
English
Country
Netherlands
Review Stage
Review Ongoing
First Submission Date
2017-01-11
Registration Date
2017-12-13
Anticipated Start Date
2016-10-15
Anticipated Completion Date
2017-12-18
Title Cn
支气管肺泡灌洗液半乳甘露聚糖检测用于免疫功能低下患者侵袭性曲霉病的诊断 [Cochrane方案]
Title En
Galactomannan detection in broncho-alveolar lavage fluid for invasive aspergillosis in immunocompromised patients [Cochrane Protocol]
Bilingual Status
complete